Pelletier Jonathan H, Au Alicia K, Fuhrman Dana, Zullo James, Thompson Ann E, Clark Robert S B, Horvat Christopher
Division of Pediatric Critical Care Medicine, Department of Critical Care Medicine, Pittsburgh, Pa. UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pa.
Data Warehouse, UPMC Children's Hospital of Pittsburgh.
Pediatr Qual Saf. 2021 Dec 15;6(6):e481. doi: 10.1097/pq9.0000000000000481. eCollection 2021 Nov-Dec.
The Centers for Disease Control and Prevention recommends tracking risk-adjusted antimicrobial prescribing. Prior studies have used prescribing variation to drive quality improvement initiatives without adjusting for severity of illness. The present study aimed to determine the relationship between antimicrobial prescribing and risk-adjusted ICU mortality in the Pediatric Health Information Systems (PHIS) database, assessed by IBM-Watson risk of mortality. A nested analysis sought to assess an alternative risk model incorporating laboratory data from federated electronic health records.
Retrospective cohort study of pediatric ICU patients in PHIS between 1/1/2010 and 12/31/2019, excluding patients admitted to a neonatal ICU, and a nested study of PHIS+ from 1/1/2010 to 12/31/2012. Hospital antimicrobial prescription volumes were assessed for association with risk-adjusted mortality.
The cohort included 953,821 ICU encounters (23,851 [2.7%] nonsurvivors). There was 4-fold center-level variability in antimicrobial use. ICU antimicrobial use was not correlated with risk-adjusted mortality assessed using IBM-Watson. A risk model incorporating laboratory data available in PHIS+ significantly outperformed IBM-Watson (c-statistic 0.940 [95% confidence interval 0.933-0.947] versus 0.891 [0.881-0.901]; 0.001, area under the precision recall curve 0.561 versus 0.297). Risk-adjusted mortality was inversely associated with antimicrobial prescribing in this smaller cohort using both the PHIS+ and Watson models ( = 0.05 and < 0.01, respectively).
Antimicrobial prescribing among pediatric ICUs in the PHIS database is variable and not associated with risk-adjusted mortality as assessed by IBM-Watson. Expanding existing administrative databases to include laboratory data can achieve more meaningful insights when assessing multicenter antibiotic prescribing practices.
美国疾病控制与预防中心建议追踪风险调整后的抗菌药物处方情况。先前的研究利用处方差异来推动质量改进举措,但未对疾病严重程度进行调整。本研究旨在确定儿科健康信息系统(PHIS)数据库中抗菌药物处方与风险调整后的重症监护病房(ICU)死亡率之间的关系,采用IBM-沃森死亡率风险评估。一项嵌套分析试图评估一种纳入来自联合电子健康记录的实验室数据的替代风险模型。
对2010年1月1日至2019年12月31日期间PHIS中的儿科ICU患者进行回顾性队列研究,排除入住新生儿ICU的患者,并对2010年1月1日至2012年12月31日期间的PHIS+进行嵌套研究。评估医院抗菌药物处方量与风险调整后死亡率之间的关联。
该队列包括953,821次ICU就诊(23,851例[2.7%]非幸存者)。抗菌药物使用存在4倍的中心水平差异。ICU抗菌药物使用与使用IBM-沃森评估的风险调整后死亡率无关。纳入PHIS+中可用实验室数据的风险模型显著优于IBM-沃森(c统计量为0.940[95%置信区间0.933-0.947],而IBM-沃森为0.891[0.881-0.901];P<0.001,精确召回曲线下面积为0.561对0.297)。在这个较小的队列中,使用PHIS+和沃森模型时,风险调整后死亡率与抗菌药物处方呈负相关(分别为P = 0.05和P<0.01)。
PHIS数据库中儿科ICU的抗菌药物处方存在差异,且与IBM-沃森评估的风险调整后死亡率无关。在评估多中心抗生素处方实践时,扩展现有行政数据库以纳入实验室数据可获得更有意义的见解。